Overview

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Status:
Completed
Trial end date:
2020-09-08
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to evaluate the efficacy of zanubrutinib in participants with centrally confirmed relapsed or refractory MCL.
Phase:
Phase 2
Details
Lead Sponsor:
BeiGene
Treatments:
Zanubrutinib